Biogen

BIIB

10 Followers

$122.38

-0.93%

-$1.15

7 August

Upcoming Earnings

Market Cap.

P/E

Overview Metrics Financials

BIIB Fair Price

$067.86

Undervalued by 18.1%

To display the fair price of a share, you need to be a member of Bulios Black.

My Notes

Začít psát

Profile

Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.